Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus
Patent Ductus Arteriosus
About this trial
This is an interventional prevention trial for Patent Ductus Arteriosus focused on measuring prematurity, chronic lung disease, necrotizing enterocolitis, indomethacin, ductus arteriosus
Eligibility Criteria
Inclusion Criteria: Newborn infants of less than 28 weeks gestational age who are treated with indomethacin during the first 48 hours after birth Presence of patent ductus arteriosus (PDA) by Doppler echocardiography between the second and third dose of indomethacin. Creatinine ≤1.8 mg/dl Platelets ≥ 50,000 Exclusion Criteria: Chromosomal disorders. Major congenital anomalies. Contraindications for indomethacin Necrotizing enterocolitis, by clinical or radiological evidence Evidence of bleeding diathesis as evidenced by pulmonary hemorrhage, persistent oozing from puncture sites, grossly bloody stool (Note: Infants with an intracranial hemorrhage can be enrolled in this study).
Sites / Locations
- University of California San Francisco
- University of Chicago
- Brown University